Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 138,443 | 107,197 | 71,893 | 44,420 | 25,397 |
| TOTAL | $142,505 | $111,169 | $75,211 | $49,051 | $29,447 |
| Non-Current Assets | |||||
| Intangibles | 1,914 | 1,914 | 1,914 | 1,914 | 1,914 |
| Other Non-Current Assets | 963 | 1,094 | 1,220 | 590 | 944 |
| TOTAL | $2,877 | $3,008 | $3,134 | $2,504 | $2,858 |
| Total Assets | $145,382 | $114,177 | $78,345 | $51,555 | $32,305 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,086 | 3,633 | 2,948 | 2,305 | 3,336 |
| Accrued Expenses | 3,903 | 2,261 | 3,525 | 3,021 | 2,083 |
| TOTAL | $7,569 | $6,456 | $7,017 | $5,925 | $5,999 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 157 | 309 | 457 | 0 | 157 |
| TOTAL | $157 | $309 | $457 | $N/A | $157 |
| Total Liabilities | $7,726 | $6,765 | $7,474 | $5,925 | $6,156 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 201,946 | 186,033 | 179,583 | 142,442 | 105,298 |
| Common Shares | 20 | 18 | 15 | 12 | 10 |
| Retained earnings | -293,000 | -283,395 | -274,988 | -267,330 | -260,539 |
| TOTAL | $137,656 | $107,412 | $70,871 | $45,630 | $26,149 |
| Total Liabilities And Equity | $145,382 | $114,177 | $78,345 | $51,555 | $32,305 |